国产精品又长又粗又爽又黄的毛片, 国产AV无码专区亚洲AV毛片搜, 丰满人妻被猛烈进入中文字幕四川, 国产精品一区二区三区国产女人喷,亚洲国产欧美日韩图片在线人,潘娇娇337p人艺体艺术,成人免费无码大片a毛片古装,一本到高清视频免费,人妻在线视频免费看

400-885-9898
更新于 12月19日
智聯(lián)APPAPP
舉報(bào)

生物高級(jí)研究員(J10606)

2-3萬(wàn)
  • 北京昌平區(qū)
  • 1-3年
  • 博士
  • 全職
  • 招1人

職位描述

生物藥抗體藥ADC
崗位職責(zé):
1. Independently design, plan and execute in vitro pharmacology experiments for biologics drugs, including but not limited to target validation, affinity determination, activity screening, dose - effect relationship research, and mechanism of action exploration.
2. Establish and optimize various in vitro pharmacology experimental models based on project requirements, such as cell - level functional experimental models and molecular interaction models.
3. Be responsible for the collection, collation, analysis and interpretation of experimental data. Use professional statistical methods to analyze experimental results, write detailed experimental reports, and timely report research progress to the team and superiors.
4. Track the latest progress and technical trends in the field of in vitro pharmacology research of biologics, introduce advanced experimental technologies and methods, and improve the research level and experimental efficiency of the team.
5. Participate in cross - departmental collaboration of drug R&D projects, communicate closely with related teams such as antibody discovery, protein science, and in vivo pharmacology.
任職要求:
1. PhD in biology, pharmacy, immunology or other related majors.
2. At least 1-2 years of relevant work experience in in vitro pharmacology research of biologics. Hands - on experience in autoimmune disease - related projects and antibody - drug conjugate (ADC) research is highly preferred. Alternatively, more than 3 years experience in aforementioned field in academia as postdoctoral researcher.
3. Proficiency in various in vitro pharmacology experimental techniques, such as ELISA, FACS, Western Blot, SPR, cell proliferation/apoptosis detection, reporter gene assay, etc., with experience in applying these techniques to autoimmune disease models and ADC activity evaluation.
4. Be able to independently operate relevant experimental instruments and equipment, such as flow cytometers, microplate readers, biomolecular interaction analyzers, etc., and can perform basic troubleshooting.
5. Strong experimental design ability and problem - solving ability, able to independently analyze and solve technical problems in the experimental process of autoimmune disease and ADC projects.
6. Good data analysis ability and scientific thinking, able to use statistical software for data processing and result analysis.
7. Good English reading and writing skills, able to proficiently read English professional literature and technical materials and write English experimental reports.

工作地點(diǎn)

昌平區(qū)北京諾誠(chéng)健華醫(yī)藥科技有限公司

職位發(fā)布者

趙女士/招聘經(jīng)理

昨日活躍
立即溝通
公司Logo諾誠(chéng)健華
諾誠(chéng)健華（上交所代碼：688428；香港聯(lián)交所代碼：09969）于2015年由世界著名結(jié)構(gòu)生物學(xué)家施一公院士和生物醫(yī)藥行業(yè)卓越的科學(xué)家兼企業(yè)家崔霽松博士聯(lián)合創(chuàng)立。作為一家植根于中國(guó)且具有全球視野的新藥創(chuàng)制公司，諾誠(chéng)健華以“科學(xué)驅(qū)動(dòng)創(chuàng)新患者所需為本”為價(jià)值理念，專注于惡性腫瘤和自身免疫性疾病的創(chuàng)新藥研究和開(kāi)發(fā)。經(jīng)過(guò)近十年的堅(jiān)實(shí)發(fā)展，公司在各方面取得重大進(jìn)展。2020年3月23日，諾誠(chéng)健華成功在港交所上市，成為2020年港交所生物醫(yī)藥第*一股。2022年9月21日，諾誠(chéng)健華在上海證券交易所科創(chuàng)板上市，開(kāi)啟了H+A的新征程。目前，諾誠(chéng)健華已經(jīng)打造了具有市場(chǎng)前景的強(qiáng)大產(chǎn)品管線，覆蓋血液瘤、實(shí)體瘤和自身免疫性疾病。諾誠(chéng)健華自主研發(fā)的國(guó)家“重大新藥創(chuàng)制”專項(xiàng)成果——BTK抑制劑奧布替尼（商品名：宜諾凱?）目前已在中國(guó)和新加坡獲批上市并納入中國(guó)國(guó)家醫(yī)保，是中國(guó)首*個(gè)且唯*一獲批針對(duì)邊緣區(qū)淋巴瘤的BTK抑制劑；坦昔妥單抗（商品名：明諾凱?）創(chuàng)新療法已成為中國(guó)首*個(gè)獲批治療復(fù)發(fā)/難治性彌漫性大B細(xì)胞淋巴瘤（R/R DLBCL）的CD19單抗；mesutoclax（ICP-248）是中國(guó)第*一個(gè)獲得突破性療法認(rèn)定（Breakthrough Therapy Designation）的BCL2抑制劑，10多款創(chuàng)新藥在臨床階段。諾誠(chéng)健華已經(jīng)構(gòu)建了從源頭創(chuàng)新、臨床開(kāi)發(fā)、生產(chǎn)到商業(yè)化的全產(chǎn)業(yè)鏈平臺(tái)。在具有豐富研發(fā)、生產(chǎn)和商業(yè)化經(jīng)驗(yàn)的管理團(tuán)隊(duì)的帶領(lǐng)下，諾誠(chéng)健華已構(gòu)建起一體化的生物醫(yī)藥平臺(tái)，包括藥物晶型研究平臺(tái)、難溶性藥物增溶制劑技術(shù)研發(fā)及產(chǎn)業(yè)化平臺(tái)、生物大分子發(fā)現(xiàn)和工程化改造平臺(tái)等，加速為全球腫瘤和自身免疫性疾病患者開(kāi)發(fā)并提供極具市場(chǎng)前景的創(chuàng)新療法。發(fā)展至今，諾誠(chéng)健華現(xiàn)有員工1200多人，眾多員工擁有海外工作和世界500*強(qiáng)藥企工作經(jīng)驗(yàn)，并擁有多名國(guó)家*級(jí)、省市級(jí)人才專家。諾誠(chéng)健華在北京、南京、上海、廣州、香港和美國(guó)等多地均設(shè)有分支機(jī)構(gòu)。
公司主頁(yè)